Boston-based drug-discovery company founded in 2021 using a 'Biodynamic Discovery Platform' to develop nature-inspired psychoactive medicines drawn from psychoactive plants and fungi. Its lead asset SENS-01 targets social anxiety disorder (Phase 1); other programs include SENS-03 for epilepsy and SENS-08 for neurodegenerative cognitive dysfunction. It closed a $30M Series A in 2022.